Form 8-K - Current report:
SEC Accession No. 0001420720-26-000010
Filing Date
2026-07-01
Accepted
2026-07-01 07:33:29
Documents
13
Period of Report
2026-07-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20260701x8k.htm   iXBRL 8-K 35850
2 EX-99.1 ibio-20260701xex99d1.htm EX-99.1 13816
  Complete submission text file 0001420720-26-000010.txt   174773

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20260701.xsd EX-101.SCH 3502
4 EX-101.DEF ibio-20260701_def.xml EX-101.DEF 2848
5 EX-101.LAB ibio-20260701_lab.xml EX-101.LAB 17254
6 EX-101.PRE ibio-20260701_pre.xml EX-101.PRE 11362
16 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20260701x8k_htm.xml XML 4805
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 261142599
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)